<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045265</url>
  </required_header>
  <id_info>
    <org_study_id>MISP35369</org_study_id>
    <nct_id>NCT01045265</nct_id>
  </id_info>
  <brief_title>Concentrations of Raltegravir in the Semen of HIV-Infected Men</brief_title>
  <official_title>Study to Determine the Concentrations of Raltegravir in Semen, the Seminal to Plasma Ratio of Raltegravir and the Variability in Seminal to Plasma Ratios Over the Raltegravir Dosing Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Immunodeficiency Research Collaborative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Immunodeficiency Research Collaborative</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine if concentrations of raltegravir in semen exceed
      the 50% and 95% inhibitory concentrations of HIV during the dose interval.

      The secondary objective is to determine the extend of raltegravir penetration into semen by
      obtaining semen to plasma ratios across the dosing interval, to determine the area under the
      concentration time curve of raltegravir in semen, and to determine the variability in the
      penetration of raltegravir into the seminal compartment over the dosing period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient population will consist of 12 male HIV-positive patients who have been receiving
      stable antiretroviral therapy that includes raltegravir for a minimum of three months.
      Patients will be enrolled from one clinic in downtown Toronto and a hospital affiliated HIV
      specialty clinic in Ottawa, Ontario. Eligible patients will have evidence of full virologic
      suppression (HIV viral load &lt; 50 copies/mL) at least one month prior to enrollment in the
      study. No changes will be made to the patients antiretroviral therapy during the course of
      the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Seminal Concentrations of Raltegravir.</measure>
    <time_frame>6 months</time_frame>
    <description>Determine if concentrations of raltegravir in semen exceed the 50% and 95% inhibitory concentrations of HIV during the dosing interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Semen to Plasma Raltegravir Concentrations</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the extent of raltegravir penetration into semen by obtaining semen to plasma ratios across the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seminal Distribution of Raltegravir</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the area under the concentration time curve of raltegravir in semen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Semen to Plasma Distribution of Raltegravir</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the variability in the penetration of raltegravir into the seminal compartment over the raltegravir dosing period.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Raltegravir treated men</arm_group_label>
    <description>Single group study of seminal plasma pharmacokinetics of raltegravir in men receiving chronic raltegravir therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Seminal plasma pharmacokinetics</intervention_name>
    <description>Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.</description>
    <arm_group_label>Raltegravir treated men</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        12 HIV-positive males
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected male

          -  18 years old or older

          -  on raltegravir twice daily as part of their antiretroviral regimen for at least 3
             months prior to screening

          -  viral load &lt; 50 copies/mL at least one month prior to enrolling

          -  able to read, understand and sign a written informed consent prior to initiation of
             the study

          -  medically stable at the time of the study, with no evidence of acute illness

        Exclusion Criteria:

          -  having difficulty adhering to current antiretroviral therapy

          -  patient is expected to have difficulties adhering with study protocol

          -  patients with malignancy, or acute renal or liver disease

          -  patient with active AIDS-defining illness

          -  patient with any medical, psychiatric or other circumstance that may impede the
             provision of informed consent

          -  patient with any of the following abnormalities at the time of screening:

          -  hemoglobin &lt; 85 g/L

          -  absolute neutrophil count &lt; 1000 cells/uL

          -  platelet count &lt; 50,000 cells/ microleter (uL)

          -  aspartate aminotransferase (AST), alanine transaminase (ALT) or total bilirubin &gt; 3
             times the upper limit of normal

          -  serum creatinine &gt; 1.5 times upper limit of normal

          -  patient receiving concomitant therapy with rifampin or St. John's wort
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Loutfy, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maple Leaf Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tony Antoniou</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Immunodeficiency Research Collaborative</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <results_first_submitted>June 16, 2014</results_first_submitted>
  <results_first_submitted_qc>August 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2014</results_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Men on Raltegravir</title>
          <description>HIV-infected men on chronic therapy with raltegravir 400 mg per day as part of antiretroviral therapy regimen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The median age and baseline CD4+ T-cell count of the study participants were 48 years (IQR 42–53) and 450 cells/mm3 (IQR 289–585).</population>
      <group_list>
        <group group_id="B1">
          <title>Men on Raltegravir</title>
          <description>Measuring semen samples: Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="42" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Count</title>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="450" lower_limit="289" upper_limit="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seminal Concentrations of Raltegravir.</title>
        <description>Determine if concentrations of raltegravir in semen exceed the 50% and 95% inhibitory concentrations of HIV during the dosing interval.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>16 Male HIV-positive Patients</title>
            <description>Measuring semen samples: Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>Seminal Concentrations of Raltegravir.</title>
          <description>Determine if concentrations of raltegravir in semen exceed the 50% and 95% inhibitory concentrations of HIV during the dosing interval.</description>
          <units>mg/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.13" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" lower_limit="1.46" upper_limit="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Semen to Plasma Raltegravir Concentrations</title>
        <description>Determine the extent of raltegravir penetration into semen by obtaining semen to plasma ratios across the dosing interval.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>16 Male HIV-positive Patients</title>
            <description>Measuring semen samples: Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>Semen to Plasma Raltegravir Concentrations</title>
          <description>Determine the extent of raltegravir penetration into semen by obtaining semen to plasma ratios across the dosing interval.</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" lower_limit="1.46" upper_limit="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seminal Distribution of Raltegravir</title>
        <description>Determine the area under the concentration time curve of raltegravir in semen.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>16 Male HIV-positive Patients</title>
            <description>Measuring semen samples: Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>Seminal Distribution of Raltegravir</title>
          <description>Determine the area under the concentration time curve of raltegravir in semen.</description>
          <units>h mg/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" lower_limit="5.24" upper_limit="13.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Semen to Plasma Distribution of Raltegravir</title>
        <description>Determine the variability in the penetration of raltegravir into the seminal compartment over the raltegravir dosing period.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>16 Male HIV-positive Patients</title>
            <description>Measuring semen samples: Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>Semen to Plasma Distribution of Raltegravir</title>
          <description>Determine the variability in the penetration of raltegravir into the seminal compartment over the raltegravir dosing period.</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" lower_limit="1.05" upper_limit="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>collected over 1.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Men on Raltegravir</title>
          <description>HIV-infected men receiving chronic therapy with raltegravir 400 mg per day as part of antiretroviral regimen.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tony Antoniou</name_or_title>
      <organization>Maple Leaf Research</organization>
      <phone>4164657936</phone>
      <email>tantoniou@smh.toronto.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

